Clinical implications of the quantitative detection of ID4 gene methylation in myelodysplastic syndrome

Table 5 Association between ID4 gene methylation status and MDS subtypes

	Total	Methylation level	P value	Methylated	P value
Patients (N)	100			27
IPSS karyotype	37		0.360	9	0.298
Good	22	0.14 (0 to 2.72)		4
Intermediate	9	0.24 (0 to 0.80)		4
Poor	6	0.04 (0 to 0.24)		1
BM blast (%)			0.098		<0.001
<5	75	0.47 (0 to 1.51)		10
5 to 10	13	0.84 (0 to 3.79)		8
11 to 19	12	1.03 (0 to 2.80)		9
IPSS cytopenias			0.734		0.787
0/1	22	0.24 (0 to 2.80)		5
2/3	78	0.20 (0 to 3.79)		22
IPSS risk group	35		0.007	9	0.002
Low-risk (low/int-1)	24	0.03 (0 to 0.76)		2
High-risk (Int-2/high)	11	0.43 (0 to 2.72)		7
WHO subtype	100			27
Risk			0.000		<0.001
Low risk	70	0.06 (0 to 1.51)		9
High risk	30	0.54 (0 to 3.79)		18
Subtype			0.000		<0.001
RA	41	0.04 (0 to 0.59)		4
RCMD	22	0.06 (0 to 0.76)		4
RARS	7	0.22 (0 to 1.51)		1
RAEB-1	21	0.41 (0 to 3.79)		11
RAEB-2	9	0.8 (0 to 2.8)		7

RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with multilineage dysplasia and ringed sideroblasts; RAEB, refractory anemia with excess of blasts; IPSS, International Prognostic Scoring System. Good: normal, −Y, del(5q) or del(20) as the sole abnormality; poor: complex (≥3 abnormalities) or chromosome 7 anomalies.

ISSN: 2047-783X